A Phase 1, Open-label, Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 in Patients With Unresectable, Recurrent, Locally-advanced, or Metastatic Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2017
At a glance
- Drugs UCB 6352 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Syndax Pharmaceuticals
- 07 Nov 2017 Status changed from recruiting to active, no longer recruiting according to a Syndax Pharmaceuticals media release.
- 07 Nov 2017 According to a Syndax Pharmaceuticals media release, dosing of patients in this trial has been completed.
- 11 Sep 2017 Status changed from not yet recruiting to recruiting.